Observational Study to Characterize the Incidence of EGFR Mutation Positive and Advanced NSCLC Patients

Inclusion Criteria

• •Patients of both sexes aged 18 or more.
• •Histologically confirmed advanced or metastatic Non-Small-Cell Lung Cancer (NSCLC) (patients stage III B unsuitable for locoregional treatment, and stage IV).
• •Chemo- naïve patients (Non-Small-Cell Lung Cancer patients who have not received first line systemic cytotoxic chemotherapy).
• •Patients with available tumoral tissue (primary tumor or metastatic area) or cytological samples including fine needle aspirates (primary tumor or metastatic area), bronchial alveolar lavage or bronchial scrapings and pleural effusion.
• •Patients who have granted their written informed consent.
• •Patients with documented positive mutation in epidermal growth factor receptor (EGFR) (M+).